Elsevier

Vaccine

Volume 24, Issue 14, 24 March 2006, Pages 2617-2626
Vaccine

The PPD-specific T-cell clonal response in UK and Malawian subjects following BCG vaccination: A new repertoire evolves over 12 months

https://doi.org/10.1016/j.vaccine.2005.12.011Get rights and content

Abstract

Mycobacterium bovis bacille Calmette Guerin vaccination protects against pulmonary tuberculosis in the United Kingdom but not in Malawi. We investigated whether a difference in the clonal T-cell response to BCG vaccination might account for this. The results of clonal analysis were compared to those obtained by skin testing and in a whole blood interferon gamma assay.

Pre-vaccination antigen specific T-cell clones were detected, but the majority of clones present 12 months after vaccination were not present earlier. The magnitude of the clonal response did not correlate well with results of the other assays. These data indicate that single assays may not be reliable and that a stable memory T-cell repertoire is slow to develop.

Introduction

The efficacy of bacille Calmette Guerin (BCG) vaccine against pulmonary tuberculosis differs between populations, being lower in tropical countries such as Malawi than in the UK [1], [2]. One hypothesis to account for this is that prior exposure to environmental mycobacteria, which are more common in tropical areas, may mask or interfere with the immune response to the BCG vaccine [3]. This notion is supported by the observation that a high proportion of young adults in Malawi, who have never received BCG, have high interferon gamma (IFNγ) responses to purified protein derivatives (PPDs) of environmental mycobacteria such as Mycobacterium avium and Mycobacterium intracellullare [4]. Furthermore, unvaccinated teenage individuals in Malawi have higher IFNγ and delayed type hypersensitivity (DTH) skin test responses to Mycobacterium tuberculosis (M.tb) PPD compared to UK schoolchildren [5]. Following BCG vaccination, IFNγ and DTH skin test responses increase more in the UK than in Malawi [5]. Thus, the magnitude of the increase in IFNγ response to M.tb PPD correlates with the level of protection afforded by BCG immunisation at the population level.

The immune response to TB has traditionally been measured using the tuberculin skin test. More recently, IFNγ production in a 6 days whole blood assay or the magnitude of the increase in production following vaccination, have been suggested to provide an immunological correlate of protection [5], [6]. IFNγ secreting cells can also be quantified by ex vivo ELISPOT, in which cells are restimulated with antigen for a short time period and activated effector T-cells detected, or the cultured ELISPOT assay which measures central memory T-cells [7], [8]. These assays measure functions of T-cells responding to M.tb antigens, but do not identify their epitope specificity nor their clonal diversity. Antigen specificity can be mapped using recombinant antigens or overlapping peptides and the response to one peptide epitope followed with MHC-peptide tetramers [9], while the clonal diversity of a response can be crudely assessed by staining responding T-cells with antibodies to TCR Vβ families [10]. However clonal diversity can be assessed more sensitively following restimulation with antigen in vitro, by molecular methods such as spectratyping or heteroduplex analysis (HDA) [11].

This study set out to compare the effect of exposure to an assumed higher level of cross reacting environmental microorganisms in Malawi on the clonal response to BCG vaccination. We hypothesised that BCG vaccination might activate pre-existing memory T-cells in Malawi induced by exposure to environmental mycobacteria, but induce a primary immune response in the UK.

We used heteroduplex analysis to analyse the T-cell clonal repertoire to M.tb PPD pre-vaccination, 3- and 12-month post-BCG vaccination in UK adolescents and Malawian young adults [11]. Whole blood IFNγ and DTH skin test responses to M.tb PPD were recorded in the same individuals to allow comparison of these to clonality following BCG vaccination.

Section snippets

Participants

In Malawi, subjects were recruited between December 2002 and May 2003 during a large comparative study of immune responses to BCG vaccination [5] in rural Karonga District, in northern Malawi. Candidates born between 1976 and 1991 were selected from the project database if they had not received BCG during the Karonga Vaccine Trial [1]. These individuals were recruited with informed written consent from the individual or guardian, including permission to perform an HIV test. Exclusion criteria

TCR Vβ family usage is similar in Malawi to Caucasian populations

To determine the most frequently used TCR Vβ families in Malawi, peripheral blood samples from 14 Malawian young adults (age range 13–23, mean 16 years, 43% male), were stained with a panel of 24 Vβ family-specific monoclonal antibodies and anti-CD3. The mean percentage of CD3+ small lymphocytes was 67% and the percentage of CD3+ cells stained by each TCR Vβ-specific monoclonal antibody is shown in Fig. 1. Comparison of these data with results from 85 Caucasian individuals [10] (data provided

Discussion

The efficacy of vaccination with BCG varies greatly between different countries [14]. One hypothesis to account for this variation is that common environmental mycobacteria or other infectious agents, which may be more prevalent in developing countries, induce cross-reactive responses that mask or interfere with the immune response to BCG [3], [14]. Certainly, exposure to environmental mycobacteria can affect the magnitude and functional characteristics of the subsequent response to BCG

Acknowledgements

This work was supported by the Edward Jenner Institute for Vaccine Research and The Wellcome Trust.

Contributors: In Malawi, we thank L. Kachiwanda, O. Mwanyongo, D. Mulawa and W.B. Sichone for field work, and S. Chagaluka, H. Kanyongoloka, A. Mwanyimbo, R. Ndhlovu and H. Moyo for laboratory assistance, M. Mponda for data entry, L. Bliss, J. Saul and A. Jahn for assistance in data management, the people in Karonga District for their cooperation. In the UK, we thank M. Hameed, S. Luke, C.

References (33)

  • G.F. Black et al.

    Patterns and implications of naturally acquired immune responses to environmental and tuberculous mycobacterial antigens in Northern Malawi

    J Infect Dis

    (2001)
  • J.J. Ellner et al.

    Correlates of protective immunity to Mycobacterium tuberculosis in humans

    Clin Infect Dis

    (2000)
  • H. McShane et al.

    Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans

    Nat Med

    (2004)
  • W.H. Reece et al.

    A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease

    Nat Med

    (2004)
  • E.J. Novak et al.

    MHC class II tetramers identify peptide-specific human CD4(+) T-cells proliferating in response to influenza A antigen

    J Clin Invest

    (1999)
  • R. van den Beemd et al.

    Flow cytometric analysis of the Vbeta repertoire in healthy controls

    Cytometry

    (2000)
  • Cited by (8)

    • CD4+CCR6+ T cells dominate the BCG-induced transcriptional signature

      2021, eBioMedicine
      Citation Excerpt :

      We found both quantitative and qualitative changes in the TCR repertoire post-vaccination i.e. both clonotypes that were present pre-vaccination and new clonotypes expanded in response to antigen-stimulation. This is similar to a previous study [74], which also found new BCG-reactive clonotypes that had expanded in response to the vaccination and that were not found before vaccination. To identify antigen-specific TCRs we used a stringent criterion and only focused on clonotypes present in replicate samples, which may not identify the complete antigen-specific repertoire within an individual.

    • Factors associated with tuberculosis infection, and with anti-mycobacterial immune responses, among five year olds BCG-immunised at birth in Entebbe, Uganda

      2015, Vaccine
      Citation Excerpt :

      However, we found no evidence that LTBI status modified the association between BCG vaccine strain and cytokine response to support this hypothesis. Second, studies have shown that the magnitude of cytokine response to mycobacterial antigen gradually reduces over time [3,41]. We found that the decline in cytokine response varied with BCG vaccine strain, with IFN-γ and IL-10 responses among children who received BCG-Danish or BCG-Bulgaria waning faster than among children who received BCG-Russia.

    • Immune Memory: the Basics and How to Trigger an Efficient Long-Term Immune Memory

      2010, Journal of Comparative Pathology
      Citation Excerpt :

      Thus an important unresolved issue remains: how long can memory persist without recruitment of new clones? Our own limited data suggests that among memory clones specific for purified protein derivative (PPD), more than 80% of CD4 clonal receptors could be detected for at least 3 years (Bennett et al., 2006), suggesting that the average lifespan of human memory T-cell clones may be many years and is seldom a limiting factor for persistence of memory. Much less is known about persistence over long periods of time of B-cell clones, but since the kinetics of memory B and T cells are similar, it is reasonable to assume that B-cell clones persist for years in man.

    • What has Karonga taught us? Tuberculosis studied over three decades

      2009, International Journal of Tuberculosis and Lung Disease
    View all citing articles on Scopus
    View full text